Animal Health/Sanidade Animal: Boletin PANAFTOSA: ZOONOSES

Este Boletín comenzó a editarse en 2006 en formato digital y continuará siendo distribuído mensualmente a la lista de suscriptos en zoonosis, para mantener la diseminación selectiva de la información escogida por sus suscriptores, a quienes solicitamos actualizar sus datos en "Change your subscription" al pie. Para quienes estén interesados en recibir el Boletín de PANAFTOSA de los restantes temas, ir a la Web de PANAFTOSA y suscribirse colocando nombre e email (columna de la izquierda, debajo del título "Boletín Electrónico").

Carbunco / Antrax

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF. Vaccine 2013 Mar; 31 (11): 1480-1489

Enfermedad de Chagas / Chagas Disease

Doença de Chagas, doença do Brasil. Marques IC. Hist Cienc Saude Manguinhos. 2013 Mar; 20 (1): 337-45

Seroepidemiological study of chagas disease in the southern Amazon region of Ecuador. Guevara AG, Atherton RD, Wauters MA, Vicuña Y, Nelson M, Prado J, Kato H, Calvopiña MH, Hashiguchi Y. Trop Med Health. 2013 Mar; 41 (1): 21-5

Influenza Aviar / Avian Influenza

Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol Rec. 2013 Mar; 88 (11): 117-25

Human infections with novel Influenza A (H7N9) viruses. CDC Health Alert Network. April 5, 2013

Update on human cases of influenza at the human-animal interface, 2012. Wkly Epidemiol Rec. 2013 Mar; 88 (11): 137-144

Leishmaniasis

Development of Leishmania vaccines: predicting the future from past and present experience. Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. J Biomed Res. 2013 Mar; 27 (2): 85-102

Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J. PLoS Negl Trop Dis. 2013 Mar;7 (3): e2130

Rabia / Rabies

Eliminating canine rabies: the role of public-private partnerships. Taylor L. Antiviral Res. 2013 Mar

Eliminating canine rabies, the principal source of human infection: What will it take? Meslin FX, Briggs D. Antiviral Res. 2013 Mar

Eliminating the scourge of dog-transmitted rabies. Dodet B, Korejwo J, Briggs DJ. Vaccine 2013; 31 (10): 1359

Evaluation of an indirect rapid immunohistochemistry test for the differentiation of rabies virus variants. Dyer JL, Niezgoda M, Orciari LA, Yager PA, Ellison JA, Rupprecht CE. J Virol Methods. 2013 Mar

Potential economic benefits of eliminating canine rabies. Shwiff S, Anderson A, Hampson K. Antiviral Res. 2013 Mar

Quantitative proteomics for identifying biomarkers for rabies. Venugopal AK, Ghantasala SS, Selvan LD, Mahadevan A, Renuse S, Kumar P, Pawar H, Sahasrabhuddhe NA, Suja MS, Ramachandra YL, Prasad TS, Madhusudhana SN, Hc H, Chaerkady R, Satishchandra P, Pandey A, Shankar SK. Clin Proteomics. 2013 Mar; 10 (1):3